Johnson & Johnson JNJ

$271.95 +0.73 (0.27%)

Valuation

Market cap
653,612,544,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
24.92
Forward PE
23.32
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
7,188,800
Avg volume
6,759,544
Day's range
$269.27 – $273.78
Shares out
2,409,898,000
Stochastic %K
68%
Beta
0.24
Analysts
Strong Sell
Price target
$281.08

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

BigAllergies Sep 29, 6:14 AM
$JNJ trend's up and it makes real money, 70th of 2,950 today
0 replies
SellasgpsCurativeBAT11 Sep 29, 4:16 AM
$AZN $JNJ $PFE $SLS $SMMT SMMT short interest before $AZN deal: Shares Short (9/15/2026) 4 41.08M Short Ratio (9/15/2026) 4 6.44 Short % of Float (9/15/2026) 4 26.26% Short % of Shares Outstanding (9/15/2026) 4 5.15% Shares Short (prior month 8/14/2026) 4 37.43M ✌️🙏❤️‍🩹
0 replies
Garibs Sep 29, 1:40 AM
$JNJ 280 this week
0 replies
SellasgpsCurativeBAT11 Sep 29, 1:38 AM
$AZN $SMMT $JNJ $PFE $SLS Another day another massive Biotech Oncology deal: $AZN Makes $2 Billion Strategic Equity Investment in Summit Therapeutics 9/28/2026 2:30pm Investment in Preferred Shares Convertible to Common Equity, Equivalent to a Per-Share Price of Summit's Common Stock of $18.36, Representing a Premium over Today's Closing Trading Price Summit Also Enters into Clinical Trial Collaboration with AstraZeneca to Evaluate Ivonescimab in Combination with Sonesitatug Vedotin in Multiple Gastrointestinal Cancers Summit & AstraZeneca Plan to Enter into a Clinical Trial Collaboration Combining Ivonescimab with Multiple AstraZeneca ADCs and Other Cancer Medicines. $SMMT has over a Billion shares out, $AZN smart move instead of Acquiring the whole Co. $JNJ $SLS Next up. ✌️🙏❤️‍🩹
0 replies
ElliottwaveForecast Sep 29, 12:52 AM
$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 replies
Buyorsell4321 Sep 28, 9:44 PM
$SMMT Duggan déjà vu! $JNJ’s PCYC deal was worth up to $975M. AbbVie later bought PCYC for $21B—$261.25/share. Now $AZN commits $2B to Summit through convertible preferred at an $18.36 common-share equivalent, plus a cancer-trial collaboration. Serious capital. Major pharma backing. HUGE vote of confidence in ivonescimab. 🚀
0 replies
MessAndGetHorns Sep 28, 5:13 PM
$ESTA https://www.forbes.com/sites/emmasandler/2026/08/17/is-motiva-preserv-the-rolls-royce-of-breast-implants/ $QQQ $SPY $JNJ $ABBV
0 replies
SellasgpsCurativeBAT11 Sep 28, 4:38 PM
$SLS $JNJ $BMY $PFE $AZN 4 Contenders. Let’s see who walks away with # 1 Oncology prize in a Millennia. GPS CURATIVE 20+ WT1 cancers. ✌️🙏❤️‍🩹
1 replies